BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Apoptosis
,
Ischemia
,
Lymphocyte
,
Neocentromeres
,
Lovastatin
,
rs7903146
,
MDM2
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
receptors interleukin- 9
Summary
General Info
Curated Studies
Most Correlated Studies
L1000 CMAP - Adenocarcinoma of breast MCF7 cells treated with ligand perturbagens
L1000 CMAP - Colorectal cancer HT29 cells treated with ligand perturbagens
L1000 CMAP - Prostate carcinoma VCaP cells treated with ligand perturbagens
L1000 CMAP - Lung cancer A549 cells treated with ligand perturbagens
L1000 CMAP - Amelanotic malignant melanoma of skin A375 cells treated with ligand perturbagens
Explore Curated Studies Results
Literature
Most Relevant Literature
Potentiating adoptive cell therapy using synthetic IL-9 receptors.
Presence and the roles of IL-9/Th9 axis in vitiligo.
Interleukin-9 regulates macrophage activation in the progressive multiple sclerosis brain.
Characterization of chicken interleukin-9 receptor alpha chain.
Combined in vitro and cell-based selection display method producing specific binders against IL-9 re…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Single Ascending Doses Study of Anti- Interleukin-7 Receptor α Monoclonal Antibody (GSK2618960) in H…
BLOC-ICH: Interleukin-1 Receptor Antagonist in Intracerebral Haemorrhage
Interleukin-1 Receptor Antagonist and Insulin Sensitivity
Interleukin and Autoantibodies in Myasthenia Gravis.
Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Le…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ